Kimberly Lathroum Joins Arcutis as Vice President of Marketing
March 23 2020 - 8:30AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, today announced
that Kimberly Lathroum has joined the company as Vice President of
Marketing. In this new role, Ms. Lathroum will be responsible for
all of Arcutis’ marketing efforts as the Company prepares for the
potential future commercialization of its product candidates.
“Kimberly is an exceptional marketing and
commercialization executive with over 18 years of experience in the
biopharmaceutical industry, 10 of which have been specifically
focused on the dermatology market,” said Frank Watanabe, Arcutis’
President and Chief Executive Officer. “Her previous success and
innovation in brand positioning and commercial launch strategy will
be a tremendous asset should we achieve clinical and regulatory
success with our robust pipeline of potentially best-in-class
dermatology product candidates.”
Previously, Ms. Lathroum was Executive Director,
Marketing for Kite Pharma. Before that she was Associate Vice
President of Marketing for City of Hope. Prior to that, she served
in multiple marketing executive roles with Amgen, primarily for
dermatology products. Ms. Lathroum holds a B.A. in English, with a
minor in Marketing.
About Arcutis - Bioscience,
applied to the skin.Arcutis is a late-stage biopharmaceutical
company focused on developing and commercializing treatments for
unmet needs in immune-mediated dermatological diseases and
conditions, or immuno-dermatology. Arcutis exploits recent
innovations in inflammation and immunology to develop potential
best-in-class therapies against validated biological targets,
leveraging our deep development, formulation and commercialization
expertise to bring to market novel dermatology treatments, while
maximizing our probability of technical success and financial
resources. Arcutis is currently developing three novel compounds
(topical roflumilast cream (ARQ-151), topical roflumilast foam
(ARQ-154) and ARQ-252) for multiple indications, including
psoriasis, atopic dermatitis, seborrheic dermatitis and eczema. For
more information, please visit www.arcutis.com or follow the
Company on LinkedIn.
Contact:John W. SmitherChief
Financial Officerjsmither@arcutis.com
Investors and Media:Heather
Rowe ArmstrongVice President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Sep 2023 to Sep 2024